» Articles » PMID: 37804534

Plasma Sphingolipid Profile of Healthy Black and White Adults Differs Based on Their Parental History of Type 2 Diabetes

Overview
Specialty Endocrinology
Date 2023 Oct 7
PMID 37804534
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Ceramides and sphingolipids have been linked to type 2 diabetes (T2D). The Ceramides and Sphingolipids as Predictors of Incident Dysglycemia (CASPID) study is designed to determine the association of plasma sphingolipids with the pathophysiology of human T2D.

Objective: A comparison of plasma sphingolipids profiles in Black and White adults with (FH+) and without (FH-) family history of T2D.

Design: We recruited 100 Black and White FH- (54 Black, 46 White) and 140 FH+ (75 Black, 65 White) adults. Fasting plasma levels of 58 sphingolipid species, including 18 each from 3 major classes (ceramides, monohexosylceramides, and sphingomyelins, all with 18:1 sphingoid base) and 4 long-chain sphingoid base-containing species, were measured by liquid chromatography/mass spectrometry.

Results: Sphingomyelin was the most abundant sphingolipid in plasma (89% in FH-), and was significantly elevated in FH+ subjects (93%). Ceramides and monohexosylceramides comprised 5% and 6% of total sphingolipids in the plasma of FH- subjects, and were reduced significantly in FH+ subjects (3% and 4%, respectively). In FH+ subjects, most ceramide and monohexosylceramide species were decreased but sphingomyelin species were increased. The level of C18:1 species of all 3 classes was elevated in FH+ subjects.

Conclusion: Elevated levels of sphingomyelin, the major sphingolipids of plasma, and oleic acid-containing sphingolipids in healthy FH+ subjects compared with healthy FH- subjects may reflect heritable elements linking sphingolipids and the development of T2D.

Citing Articles

Elevated Very-Long-Chain Ceramides in the Vitreous Humor of Patients With Proliferative Diabetic Retinopathy.

Chen Y, Yang C, Yang C, Ho T, Hsieh Y, Lai T Invest Ophthalmol Vis Sci. 2025; 66(2):28.

PMID: 39932474 PMC: 11817849. DOI: 10.1167/iovs.66.2.28.

References
1.
Fox T, Kester M . Therapeutic strategies for diabetes and complications: a role for sphingolipids?. Adv Exp Med Biol. 2010; 688:206-16. DOI: 10.1007/978-1-4419-6741-1_14. View

2.
Nyenwe E, Ogwo C, Owei I, Wan J, Dagogo-Jack S . Parental history of type 2 diabetes is associated with lower resting energy expenditure in normoglycemic subjects. BMJ Open Diabetes Res Care. 2018; 6(1):e000511. PMC: 5992470. DOI: 10.1136/bmjdrc-2018-000511. View

3.
Zhao Y, Wu S, Liu S, Zhang Y, Lin R . Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem Biol Interact. 2014; 220:181-92. DOI: 10.1016/j.cbi.2014.06.029. View

4.
Chen G, Chai J, Yu B, Michelotti G, Grove M, Fretts A . Serum sphingolipids and incident diabetes in a US population with high diabetes burden: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Am J Clin Nutr. 2020; 112(1):57-65. PMC: 7326587. DOI: 10.1093/ajcn/nqaa114. View

5.
Wilmott L, Grambergs R, Allegood J, Lyons T, Mandal N . Analysis of sphingolipid composition in human vitreous from control and diabetic individuals. J Diabetes Complications. 2019; 33(3):195-201. PMC: 6368445. DOI: 10.1016/j.jdiacomp.2018.12.005. View